AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
F   5.84 (+3.36%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BAC   24.28 (+7.15%)
BA   144.73 (+5.24%)
Log in

NYSEAMERICAN:TRXCTransEnterix Stock Price, Forecast & News

$0.42
+0.00 (+0.60 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.40
Now: $0.42
$0.43
50-Day Range N/A
52-Week Range
$0.28
Now: $0.42
$25.22
Volume903,200 shs
Average Volume1.87 million shs
Market Capitalization$21.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Read More
TransEnterix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$21.90 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of TransEnterix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for TransEnterix.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for TransEnterix.

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) posted its quarterly earnings results on Thursday, May, 14th. The medical instruments supplier reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.12. The medical instruments supplier had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.54 million. View TransEnterix's earnings history.

What price target have analysts set for TRXC?

1 brokerages have issued 12 month price targets for TransEnterix's stock. Their forecasts range from $1.00 to $1.00. On average, they expect TransEnterix's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 136.7% from the stock's current price. View analysts' price targets for TransEnterix.

Has TransEnterix been receiving favorable news coverage?

Press coverage about TRXC stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TransEnterix earned a news impact score of -1.9 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutTransEnterix.

Are investors shorting TransEnterix?

TransEnterix saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 3,150,000 shares, a drop of 6.3% from the April 15th total of 3,360,000 shares. Based on an average daily trading volume, of 1,750,000 shares, the short-interest ratio is presently 1.8 days. Approximately 9.8% of the shares of the stock are short sold. View TransEnterix's Current Options Chain.

Who are some of TransEnterix's key competitors?

What other stocks do shareholders of TransEnterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransEnterix investors own include Oramed Pharmaceuticals (ORMP), Compugen (CGEN), Editas Medicine (EDIT), Ekso Bionics (EKSO), XOMA (XOMA), Actinium Pharmaceuticals (ATNM), Geron (GERN), NVIDIA (NVDA), Advanced Micro Devices (AMD) and Opko Health (OPK).

Who are TransEnterix's key executives?

TransEnterix's management team includes the following people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.72%), BlackRock Inc. (2.51%), First Trust Advisors LP (1.31%), Russell Investments Group Ltd. (0.89%), State Street Corp (0.60%) and Perkins Capital Management Inc. (0.49%). Company insiders that own TransEnterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Todd Pope, William N Starling Jr and William N Starling, Jr. View institutional ownership trends for TransEnterix.

Which institutional investors are selling TransEnterix stock?

TRXC stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, and Morgan Stanley. View insider buying and selling activity for TransEnterix.

Which institutional investors are buying TransEnterix stock?

TRXC stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, Russell Investments Group Ltd., State Street Corp, Perkins Capital Management Inc., BlackRock Inc., Invesco Ltd., Two Sigma Investments LP, and First Trust Advisors LP. View insider buying and selling activity for TransEnterix.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $0.42.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $21.90 million.

What is TransEnterix's official website?

The official website for TransEnterix is www.transenterix.com.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.